Tevogen Bio Holdings Inc. Share Price & Technical Analysis
TVGN · $8.57 (-10.82%)
Healthcare / Biotechnology
$8.57
-10.82%
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 pat…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
39% return in May, 4% avg return in past 3 year May month.
2% return in 2026, 76% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | -8% | -65% | 47% | 39% | – | – | – | – | – | – | – | 2% |
| 25 | 45% | -10% | -16% | -7% | 28% | -3% | -20% | -9% | -14% | -21% | -30% | -27% | -83% |
| 24 | -53% | 46% | -50% | -74% | -13% | -12% | -14% | -19% | -26% | 588% | -47% | -22% | 304% |
| 23 | 0% | 4% | -2% | 2% | -2% | -1% | 0% | 1% | 1% | 0% | 2% | 1% | 6% |
| 22 | 2% | -4% | 1% | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% | 1% | 1% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$29.32M
P/E ratio
—
52W high
$75.50
52W low
$4.13
Volume
8,164
Beta
0.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tevogen Bio Holdings Inc. share price today?
- Tevogen Bio Holdings Inc. (TVGN) last traded around $8.57 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TVGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TVGN. Download the app for real-time alerts.
- How can I analyze Tevogen Bio Holdings Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.